Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.
about
Erythropoiesis-stimulating agents for anaemia in chronic heart failure patientsPopulation pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemateA Review of the External Validity of Clinical Trials with Beta-Blockers in Heart FailureThirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-AnalysisPharmacologic Update - Beta Blockers in Treatment of Heart Failure and Hypertension in Diabetes: Ugly Misconceptions Slain by Beautiful Clinical Data.Evaluation and treatment strategies in patients at high risk of sudden death post myocardial infarction.Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model.Relation of beta-blocker use with frequency of hospitalization for heart failure in patients with left ventricular diastolic dysfunction (from the Heart and Soul Study)Major beta blocker mortality trials in chronic heart failure: a critical review.Clinical Pharmacology of Carvedilol.Sympathetic activation and the role of beta-blockers in chronic heart failure.Novel treatment approaches in hypertensive type 2 diabetic patientsCurrent issues regarding beta-adrenergic blockade in patients with congestive heart failure: patient selection, nonselective versus selective blockade, management of adverse effects, and indications for withdrawal of therapy.Beta-blockers and amiodarone for the primary prevention of sudden cardiac death.beta-blockers in heart failure: recently completed and ongoing clinical trials.beta-blocker therapy: a standard of care for heart failure.beta-Blockers in congestive heart failure.Beta blockers for CHF. Adrenergic blockade dramatically reduces morbidity and mortality.Digitalis for treatment of congestive heart failure in patients in sinus rhythm.Carvedilol versus other beta-blockers in heart failure.Economics of chronic heart failure.Impact of combined clenbuterol and metoprolol therapy on reverse remodelling during mechanical unloading.Clinical trials of antiarrhythmic drugs in postmyocardial infarction and congestive heart failure patients.Beta-blocker treatment in heart failure.Carvedilol in the failing heart.Role of race in the pharmacotherapy of heart failure.Surrogate end points in heart failure.The importance of early intervention in CHF--signs and symptom relief.β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trialsComparison of the epidemiology and co-morbidities of heart failure in the pediatric and adult populations: a retrospective, cross-sectional study.CHARITY: Chagas cardiomyopathy bisoprolol intervention study: a randomized double-blind placebo force-titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy [NCT00323973].[Cardiac sequelae of hypertension].Smad3 inactivation and MiR-29b upregulation mediate the effect of carvedilol on attenuating the acute myocardium infarction-induced myocardial fibrosis in rat.Contemporary use of beta receptor antagonists in chronic heart failure.Beta-blocker benefit according to severity of heart failure.Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure.Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study.Selection of endpoints for heart failure clinical trials.Beta-blockade in heart failure: selective versus nonselective agents.Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET.
P2860
Q24241045-1A49B59B-2910-4B8F-ABED-031FF8AA2C7DQ24647717-A884E834-238C-48D0-8DED-486062EF75CFQ28068618-BE36447F-6842-4CA0-BE90-68C1F933F3FEQ30239022-ED497135-160A-4818-ADB4-74CAAC8B3F91Q30654695-FAE5E2AF-16FC-480A-987F-9685E8E58090Q33175341-5E46F86B-360B-4619-ABA7-7E6F2616C5C6Q33606538-3D58C6EA-4F6E-497F-8006-DFC379823FE5Q33682749-B9A3C31A-8DF7-4FAB-98D2-E8903BE3EA83Q33780871-805CC059-80F1-46AB-ACAF-B728C6DCEFDBQ33843419-AC4FA32E-FDC3-4D68-8B0B-511BDDE114B2Q33951267-95D7249F-0E78-4D14-ADA9-57DAA517D058Q34023579-9D77CFF8-753A-4A99-B05A-8C6C3DF59EBCQ34027213-7CFF3113-0215-4F5C-AFB8-0BBE0EE37F9BQ34027338-A5645C3B-77B1-4EBD-B2C5-368748F65267Q34074729-8B0935AC-9BCD-4B1D-9F8E-11E7657E0C97Q34088204-41DFCB64-4C45-454A-A46E-62789387EABDQ34119535-E050E460-5CC8-4C01-9EBA-73375DA7F5BCQ34193584-BDF1FFE9-E983-4904-9F2B-E822A6EE0D66Q34202664-CEFD4DD6-CF15-4393-836B-BEE7D3D1E10AQ34232069-9FD3A443-3F2D-43BA-9DE1-148676A9F88AQ34264676-EACE10A5-03BE-4D3A-A276-630B6940B39BQ34275561-4609AAB8-C0B1-4E91-98E7-9390DAA0418BQ34308130-D3776C00-2E80-4293-A999-641332D4608BQ34316468-807FAB37-DB7B-41B5-9B7A-09536AC366B9Q34478931-17251BCC-2106-4683-841C-3E494F8CD94BQ34564305-BEFEA49C-A268-435E-B088-A459F270EBE5Q34564309-E7ED008C-E086-40E8-AE07-0D470C4691D6Q34610087-00143EC2-1C98-480D-AC54-D3C3BB3001AAQ34815329-4E18267F-EF94-4DB0-B98C-7AF68364CDF4Q34945026-3C3EABF3-9951-4B09-A859-674730C62AB2Q34973539-05B6EE36-016A-47C6-AD0B-BFCCBA2A5797Q34973985-F56CE6C3-A34F-45A5-958F-A16689B3D7D2Q35005754-CC7F40A6-F24A-4939-A5A9-FB181D0CCED0Q35036013-05D502C7-A43D-4324-80A7-0EF7AD556FAEQ35150702-7D9A3E4C-2345-43DE-A69A-533DAFE142DBQ35566637-C29C3AE6-1347-4761-9CBE-A1D69158783CQ35582518-592F322C-B2C6-4A3C-AD5C-625810BD2083Q35607862-8B294E88-7FBC-4BA0-B51E-58F824DF6AB5Q35631382-24ED09C1-A8B8-4723-9D79-9F054D5D1126Q35985739-1827FD1B-7AC6-4ABC-9FBC-01E949383B86
P2860
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Carvedilol inhibits clinical p ...... lol Heart Failure Study Group.
@en
Carvedilol inhibits clinical p ...... lol Heart Failure Study Group.
@nl
type
label
Carvedilol inhibits clinical p ...... lol Heart Failure Study Group.
@en
Carvedilol inhibits clinical p ...... lol Heart Failure Study Group.
@nl
prefLabel
Carvedilol inhibits clinical p ...... lol Heart Failure Study Group.
@en
Carvedilol inhibits clinical p ...... lol Heart Failure Study Group.
@nl
P2093
P1433
P1476
Carvedilol inhibits clinical p ...... lol Heart Failure Study Group.
@en
P2093
B F Uretsky
E M Gilbert
J A Bowers
J D Sackner-Bernstein
M B Fowler
M R Bristow
R Hershberger
P304
P356
10.1161/01.CIR.94.11.2800
P407
P577
1996-12-01T00:00:00Z